Visit the Emergent website >
Choncept - Biotechnology Innovation | An Emergent Company



Choncept, L.L.C.

Choncept is a biotech company focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products. Chondroitin produced by the gene patented by Choncept is unsulfated which can be sulfated to produce chondroitin similar to that isolated from animal sources. The unsulfated chondroitin may also be of interest as a biomaterial. Chondroitin produced recombinantly may be significantly less expensive to produce than current methods that rely on animal by-products. Modified chondroitin, dermatan sulfate, has properties as an anti-coagulant, an important pharmaceutical market.

Choncept is seeking collaborative partners in several areas of development:

  • Partners with existing market channels for the distribution of nutraceutical and medical grade chondroitin sulfate
  • Partners for Dermatan sulfate development as an anti-coagulant for the $2 billion anti-coagulation market
Online Articles
    Carbohydrate Article
    Glycosaminoglycan Article
    Molecular Cloning Article
    Monodisperse Heparosan & Novel Sugar Article

Carbohydrate Links

Recent Publications